1. Home
  2. DXLG vs LGVN Comparison

DXLG vs LGVN Comparison

Compare DXLG & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Destination XL Group Inc.

DXLG

Destination XL Group Inc.

HOLD

Current Price

$0.73

Market Cap

38.4M

ML Signal

HOLD

Logo Longeveron Inc.

LGVN

Longeveron Inc.

HOLD

Current Price

$0.81

Market Cap

34.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DXLG
LGVN
Founded
1976
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.4M
34.0M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
DXLG
LGVN
Price
$0.73
$0.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$1.50
$3.00
AVG Volume (30 Days)
93.1K
367.9K
Earning Date
05-28-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.76
EPS
N/A
N/A
Revenue
$435,017,000.00
$709,000.00
Revenue This Year
$3.85
N/A
Revenue Next Year
$4.09
$10.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.44
$0.48
52 Week High
$1.69
$1.80

Technical Indicators

Market Signals
Indicator
DXLG
LGVN
Relative Strength Index (RSI) 61.31 47.89
Support Level $0.48 $0.74
Resistance Level $0.82 $0.86
Average True Range (ATR) 0.07 0.06
MACD 0.00 -0.00
Stochastic Oscillator 58.35 62.76

Price Performance

Historical Comparison
DXLG
LGVN

About DXLG Destination XL Group Inc.

Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store and Direct business. The company have two principal operating segments: company's stores and direct business.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Share on Social Networks: